- |||||||||| GC376 / Anivive, anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center
Journal: Acriflavine and proflavine hemisulfate as potential antivirals by targeting M. (Pubmed Central) - Nov 9, 2022
Our study demonstrated that ACF and PRF were inhibitors of M, and ACF has been previously reported as a PL inhibitor. Taken together, ACF and PRF might be dual-targeted inhibitors to provide protection against infections of coronaviruses.
- |||||||||| anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center
Journal: Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. (Pubmed Central) - Oct 9, 2022
The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs)...These novel bispecific antibodies are strong candidates for the treatment and prevention of infection with the Omicron, BA.2, VOCs, and other sarbecoviruses. Engineering bispecific antibodies based on non-Omicron NAbs could turn the majority of NAbs into a powerful arsenal to aid the battle against the pandemic.
- |||||||||| disitertide (P144) / Avadel, Digna Biotech, anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center
Journal: Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. (Pubmed Central) - Sep 18, 2022
Similarly, we found that levels of preexisting S2 and P144-specific antibodies correlated positively with RBD binding antibody titers after two doses of inactivated SARS-CoV-2 vaccination in human. Collectively, our study revealed an alternative origin of preexisting S2-targeted antibodies and disclosed a previously neglected aspect of the impact of gut microbiota on host anti-SARS-CoV-2 immunity.
- |||||||||| anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center
Journal: An Open, Prospective Cohort Study of VV116 in Chinese Participants Infected with SARS-CoV-2 Omicron Variants. (Pubmed Central) - Jun 8, 2022
P2/3, P3
VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies...A total of 9 adverse events with no serious adverse events were reported in the VV116 group, 7 of which were mild liver function abnormalities, and all of them were resolved without intervention. VV116 is a safe, effective oral antiviral drug, which shows a better performance within the early onset of omicron infection.Trial registration: ClinicalTrials.gov identifier: NCT05242042.Trial registration: ClinicalTrials.gov identifier: NCT05279235.Trial registration: ClinicalTrials.gov identifier: NCT05341609.
- |||||||||| anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center
Journal: Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease. (Pubmed Central) - May 22, 2021
Eighty-five COVID-19 patients were enrolled for detection of SARS-CoV-2 viral antigens, including 57 anti-SARS-CoV-2 antibody negative cases and 28 antibody positive cases...Furthermore, positive antigen detection indicated disease progression, nine cases with positive antigen (9/30, 30.0%), in contrast to two cases (2/27, 7.40%) (p = 0.0444) with negative antigen, which progressed into severe disease. Thus, the viral antigens were persistent in early stages of infection when virus was in highly replicating status, and viral antigen detection promises to rapidly screen positive patients in the early stage of SARS-CoV-2 infection.
|
